Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMAP-CAP
NCT02735707Phase 3Recruiting
- Start
- Apr 2016
- Primary completion
- Jun 2028
- Modality
- Antibody Conjugates, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of ceftriaxone, moxifloxacin, levofloxacin, piperacillin + tazobactam, ceftaroline fosamil in community acquired pneumonia (CAP), coronavirus disease 2019 (COVID-19), influenza, acute respiratory tract infection (ARTI). Started Apr 2016; status: recruiting.
02
Drugs
ceftriaxonemoxifloxacinlevofloxacinpiperacillin + tazobactamceftaroline fosamil
03
Conditions
community acquired pneumonia (CAP)coronavirus disease 2019 (COVID-19)influenzaacute respiratory tract infection (ARTI)
Beyond the preview
Go deeper on NCT02735707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735707.